AERI Aerie Pharmaceuticals, Inc.

44.85
-0.15  -0.33%
Previous Close 45.00
Open 45.15
Price To book 11.70
Market Cap 1.50B
Shares 33,382,000
Volume 453,149
Short Ratio 11.43
Av. Daily Volume 368,331

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 Mercury 1 data released September 14, 2016. Primary endpoint met. Mercury 2 trial data due 2Q 2017.
Roclatan - Mercury trials
Glaucoma
NDA Filing September 6, 2016 withdrawn due to third party manufacturing issues. NDA to be refiled towards the end of 1Q 2017.
Rhopressa
Glaucoma

Latest News

  1. Coverage initiated on Aerie Pharma by ROTH Capital
  2. Aerie Pharmaceuticals to Present at the RBC Capital Markets 2017 Global Healthcare Conference
  3. Post Earnings Coverage as Eli Lilly's Q4 Revenue Beat Market Estimates
  4. Aerie Pharmaceuticals Announces Appointment of Huan Sheng, M.D., Ph.D., as Director Clinical Research and Drug Safety
  5. Aerie Pharmaceuticals Announces Appointment of Barry Ivin as Site Director of New Manufacturing Plant in Ireland
  6. Aerie Pharmaceuticals Announces Appointment of Barry Ivin as Site Director of New Manufacturing Plant in Ireland
  7. Aerie Pharmaceuticals Announces Appointment of Kristine Erickson, O.D., Ph.D., as Vice President Clinical Research
  8. AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  9. Aerie Pharmaceuticals Enters into Lease Agreement for New Manufacturing Plant in Ireland
  10. Aerie Pharmaceuticals Enters into Lease Agreement for New Manufacturing Plant in Ireland
  11. Aerie (AERI) Rhopressa Regulatory Application Delayed Again
  12. Dow books 7th straight weekly gain in muted preholiday trade
  13. Markets Open Flat Heading Into the Holidays
  14. Aerie Pharmaceuticals' stock set to selloff after FDA inspection delay
  15. AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  16. Aerie Pharmaceuticals Provides Update on Timing of NDA Filing for RhopressaTM (netarsudil ophthalmic solution) 0.02%
  17. AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  18. Aerie Pharmaceuticals Announces Appointment of Judith J. Robertson as Chief Commercial Officer
  19. Hedge Funds Aren’t Banking On PennyMac Mortgage Investment Trust (PMT)
  20. Should You Buy Aerie Pharmaceuticals Inc (AERI)?